Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03164616 · ClinicalTrials.gov registry record · Phase 3
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
A Phase 3 study of Non-small Cell Lung Cancer (NSCLC), sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 1,186
- Enrollment target
- 20
- Study locations
NCT03164616 is a Phase 3 study of Non-small Cell Lung Cancer (NSCLC) that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 1,186 participants, above the 268-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (343% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT03164616, a Phase 3 study of Non-small Cell Lung Cancer (NSCLC), is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,186 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy + Standard of care (SoC) chemotherapy or durvalumab monotherapy + SoC chemotherapy versus SoC chemotherapy alone as first line treatment in patients with metastatic non small-cell lung cancer (NSCLC) with tumors that lack activating epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusions.
Conditions Studied
Interventions
- DRUG Durvalumab
- DRUG Tremelimumab
- DRUG Abraxane + carboplatin
- DRUG Gemcitabine + cisplatin
- DRUG Gemcitabine + carboplatin
Study Locations (20)
Florida
- Research Site - Fort Myers
- Research Site - Jacksonville
- Research Site - St. Petersburg
- Research Site - West Palm Beach
Other
- Research Site - Barretos
- Research Site - Belo Horizonte
- Research Site - Curitiba
- Research Site - Porto Alegre
California
- Research Site - Bakersfield
- Research Site - Santa Monica
Tennessee
- Research Site - Chattanooga
- Research Site - Nashville
Texas
- Research Site - Fort Worth
- Research Site - Houston
Arizona
- Research Site - Phoenix
Kentucky
- Research Site - Louisville
Missouri
- Research Site - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,186 participants |
| Start Date | 2017-06-01 |
| Est. Completion | 2027-11-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03164616
The ClinicalTrials.gov registry entry for NCT03164616 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,186 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 268-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (343% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 5 interventions - of which Durvalumab is the first listed.
NCT03164616 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, Other, California.
Frequently Asked Questions
What is clinical trial NCT03164616 about?
NCT03164616 is a clinical study titled "Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).". This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy + Standard of care (SoC) chemotherapy or durvalumab monotherapy + SoC chemotherapy versus SoC chemotherapy alone as first line treatment in pa...
What is the current status of trial NCT03164616?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,186 participants. The study started on 2017-06-01. Estimated completion is 2027-11-15.
What conditions does trial NCT03164616 study?
This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC).
What interventions are being tested in trial NCT03164616?
The interventions under investigation include: Durvalumab (DRUG), Tremelimumab (DRUG), Abraxane + carboplatin (DRUG), Gemcitabine + cisplatin (DRUG), Gemcitabine + carboplatin (DRUG).
Who is sponsoring clinical trial NCT03164616?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03164616 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Kentucky, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-small Cell Lung Cancer (NSCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
RECRUITING · Phase 3
-
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
RECRUITING · Phase 3
-
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
RECRUITING · Phase 3
-
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
RECRUITING · Phase 3
-
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.